Biospecimen and Pathology Core

生物样本和病理学核心

• 批准号: 10706321
• 负责人: Matthew M. Yeh
• 金额: $ 14.26万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-06 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10706321
• 关键词: Alaska; Alaska Native; American Indians; Area; Biological Assay; Biological Markers; Biological Specimen Banks; Cessation of life; Cherokee Indian; Chronic viral hepatitis; Cirrhosis; Classification; Clinical; Collaborations; Colorectal Cancer; Development; Early Diagnosis; Ensure; Epidemiology; Ethics; Face; Functional disorder; Future; Health Services; Hepatitis; Histology; Immunohistochemistry; Incidence; Liver; Liver diseases; Malignant Neoplasms; Malignant neoplasm of liver; Malignant neoplasm of lung; Malignant neoplasm of prostate; Microdissection; Native-Born; Oklahoma; Pathology; Patient Recruitments; Patients; Pattern; Persons; Plasma; Primary carcinoma of the liver cells; Research; Research Personnel; Research Project Grants; Resources; Sampling; Serum; Services; Source; Specimen; Stains; Texas; Tissues; Universities; Washington; Woman; biobank; cancer health disparity; chronic liver disease; cohort; digital; disparity elimination; improved; innovation; malignant breast neoplasm; men; mortality; multi-ethnic; multi-racial; novel; operation; programs; prospective; recruit; repository; research study; translational approach; tribal community; tribal health

ABSTRACT: BIOSPECIMEN AND PATHOLOGY CORE The purpose of the Biospecimen and Pathology Core is to provide biospecimens and pathology services to support the two planned Li-CAD P20 Projects and those research studies proposed in the context of the Developmental Research Program and to prepare for a P50 SPORE expansion of services. The Biospecimen Core provides expertise in the interpretation of tissue-based assays especially in the context of biomarker studies, ensures quality standards and the ethical use of biospecimens and provides Core services in histology, digital histology, immunohistochemistry and microdissection for Li-CAD investigators. SA1. Provide biospecimens needed for Projects 1 and 2 from AI/AN patients with liver disease, cirrhosis and HCC, as well as from appropriate non-AI/AN comparison/control patients Our Li-CAD project will obtain plasma, serum, liver tissue and HCC tissue specimens from the following biorepositories that will support the Li-CAD P20 studies: 1) a truly remarkable and unique biospecimen bank of samples from Alaska Native (AN) patients with chronic liver disease (“AN biorepository”) from the Alaska Native Tribal Health Consortium (ANTHC); 2) a biospecimen bank of samples from American Indian (AI) patients with chronic liver disease from the Cherokee Nation Health Service (CNHS) (“AI biorepository”) ; and 3) two large non-AI/AN, multiracial/multiethnic biorepositories, that will provide comparison specimens from non-AI/AN patients. The AN biorepository includes >40,000 prospectively and longitudinally collected biospecimens from >3500 patients at the Liver Disease and Hepatitis Program of the ANTHC (Anchorage, AK). This is directed by Dr. Brian McMahon, the PI of the Li-CAD Biospecimen Core and co-PI of the P20 Li-CAD, which will serve to streamline access to these biospecimens for Li-CAD investigators. Biospecimens from these biorepositories will support Projects 1 and 2, as well as future developmental research projects and expanded P50 projects SA2. Expand the biospecimen repository of American Indian patients with liver disease, cirrhosis and HCC based at Cherokee Nation Health Service (CNHS, Tahlequah, OK) and pattern it after our existing, large biorepository of Alaska Native patients at ANTHC. We will augment our biospecimens and patient recruitment from American Indian patients by a new collaboration with Cherokee Nation Health Service (CNHS). We will use our expertise from Alaska Native biorepositories to establish analogous liver disease biorepositories for American Indian patients at CNHS. This will be an invaluable resource, especially as we expand to a P50 SPORE. SA3. Provide core pathology resources in histology, digital histology, immunohistochemistry and microdissection for Li-CAD investigators

摘要：生物样本和病理学核心 生物样本和病理学核心的目的是为以下人员提供生物样本和病理学服务： 支持两个计划中的 Li-CAD P20 项目以及在 发展研究计划并为 P50 SPORE 服务扩展做准备。生物样本 Core 提供解释基于组织的检测的专业知识，尤其是在生物标志物方面 研究，确保生物样本的质量标准和道德使用，并提供核心服务 为 Li-CAD 研究人员提供组织学、数字组织学、免疫组织化学和显微解剖。 SA1。提供项目 1 和 2 所需的来自患有肝病的 AI/AN 患者的生物样本， 肝硬化和 HCC，以及来自适当的非 AI/AN 比较/对照患者 我们的Li-CAD项目将从以下来源获取血浆、血清、肝组织和HCC组织标本 支持 Li-CAD P20 研究的生物样本库：1) 一个真正卓越且独特的生物样本库 来自患有慢性肝病的阿拉斯加原住民 (AN) 患者的样本（“AN 生物样本库”）来自阿拉斯加原住民 部落健康联盟（ANTHC）； 2) 美洲印第安人 (AI) 患者的生物样本库 来自切罗基国家卫生服务中心 (CNHS) 的慢性肝病（“AI 生物存储库”）； 3）两个大 非 AI/AN、多种族/多民族生物样本库，将提供来自非 AI/AN 的比较样本 患者。 AN 生物样本库包含来自超过 3500 个前瞻性和纵向收集的超过 40,000 个生物样本 ANTHC（阿拉斯加州安克雷奇）肝病和肝炎项目的患者。这是布莱恩博士执导的 McMahon，Li-CAD 生物样本核心的 PI 和 P20 Li-CAD 的联合 PI，这将有助于简化 Li-CAD 研究人员可以访问这些生物样本。来自这些生物样本库的生物样本将支持 项目1和2，以及未来的发展研究项目和扩展的P50项目 SA2。扩大美洲印第安人肝病、肝硬化和肝病患者的生物样本库 HCC 位于切罗基国家卫生服务中心（CNHS，塔勒阔，俄克拉何马州），并按照我们现有的、 ANTHC 的阿拉斯加原住民患者大型生物样本库。 我们将通过新的方法来增加我们的生物样本和从美洲印第安人患者中招募的患者 与切罗基国家卫生服务中心 (CNHS) 合作。我们将利用阿拉斯加原住民的专业知识 生物储存库为 CNHS 的美国印第安人患者建立类似的肝病生物储存库。这 将是宝贵的资源，特别是当我们扩展到 P50 SPORE 时。 SA3。提供组织学、数字组织学、免疫组化等核心病理学资源 供 Li-CAD 研究人员使用的显微解剖